DC-CIK治疗对晚期肝细胞癌患者免疫功能及循环肿瘤细胞的影响

目的:研究DC-CIK细胞治疗对晚期肝细胞癌患者甲胎蛋白、免疫功能及循环肿瘤细胞数的影响。方法:选取2013年至2015年我院收治的26例肝细胞癌并伴有复发或转移的患者,对其治疗前后甲胎蛋白、免疫功能及循环肿瘤细胞数的数据进行分析,比较DC-CIK细胞治疗前后甲胎蛋白、循环肿瘤细胞、免疫功能的变化。根据细胞治疗次数分为1次组及1次组,比较两组免疫功能的变化。结果:DC-CIK细胞治疗前甲胎蛋白为(603.32±155.78)ng/mL细胞回输后为(571.24±147.49)ng/mL差异无统计学意义(P0.05)。DC-CIK细胞治疗前及细胞回输后CTC检测阳性率分别为81.8%、36.4%治疗前及回输后循环肿瘤细胞数量分别为(8.36±10.642)、(1.55±2.464),细胞治疗前后比较差异均有统计学意义(P0.05)。细胞治疗前1天T细胞亚群CD3+、CD3~+CD4~+、CD3~+CD8~+、CD4/CD8分别为(66.05±15.31)%、(41.89±12.33)%、(23.15±8.05)%、(2.10±0.77),回输后分别为(69.69±12.91)%、(44.80±11.11)%、(23.13±7.12)%、(2.29±0.91)治疗前后比较差异无统计学意义(P0.05)。细胞治疗次数1次组和1次组免疫功能变化差异无统计学意义(P0.05)。结论:DC-CIK细胞治疗可减少肝细胞癌伴复发或转移患者循环肿瘤细胞的数量,但对甲胎蛋白和免疫功能无明显影响。

The Effects of DC-CIK Therapy on Immune Function and Circulating Tumor Cells in Patients with Advanced Hepatocellular Carcinoma

Objective:To investigate the effects of DC-CIK cell therapy on AFP, immune function and number of circulating tumor cell in patients with advanced hepatocellular carcinoma.Methods:26 cases of hepatocellular carcinoma with recurrence or metastasis were selected from 2013 to 2015, the data of AFP, immune function and number of circulating tumor cell were analyzed before and after DC-CIK treatment, the changes of AFP, immune function and number of circulating tumor cell were compared. Based on frequency of cell therapy, the patients were divided into 1 time group and more than 1 time group, the changes of immune function were compared between two groups.Results:AFP was (603.32± 155.78) ng/mL one day before DC-CIK cell therapy and (571.24± 147.49) ng/mL after reinfusion (P>0.05). One day before DC-CIK cell therapy and after cell transfusion, the positive rate of CTC were 81.8 %, 36.4 % respectively; number of circulating tumor cells were (8.36 ± 10.642), (1.55 ± 2.464) one day before treatment and after the reinfusion respectively (P<0.05). The CD3+, CD3+ CD4+, CD3+ CD8+, CD4/CD8 were (66.05± 15.31) %, (41.89± 12.33) %, (23.15± 8.05) %, (2.10± 0.77) one day before treatment and (69.69± 12.91) %, (44.80± 11.11) %, (23.13± 7.12) %, (2.29± 0.91 ) after infusion respectively (P>0.05). The immune function showed no statistic significance between 1 time group and more than 1 time group (P>0.05).Conclusion:DC-CIK cell therapy could reduce number of circulating tumor cells in patients suffering from hepatocellular carcinoma with recurrence or metastasis, but had no significant effect on the serumAFP level and immune function.